Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.

Michael G. Fehlings, Jefferson R. Wilson, Ralph F. Frankowski, Elizabeth G. Toups, Bizhan Aarabi, James S. Harrop, Christopher I. Shaffrey, Susan J. Harkema, James D Guest, Charles H. Tator, Keith D. Burau, Michele W. Johnson, Robert G. Grossman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of glutamatergic toxicity, is currently an approved drug that attenuates the extent of neuronal degeneration in patients with amyotrophic lateral sclerosis. Moreover, several preclinical SCI studies have associated riluzole administration with improved functional outcomes and increased neural tissue preservation. Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. The current review summarizes the existing preclinical and clinical literature on riluzole, provides a detailed description of the Phase I trial, and suggests potential opportunities for future investigation. Clinical trial registration no.: NCT00876889.

Original languageEnglish
Pages (from-to)151-156
Number of pages6
JournalJournal of neurosurgery. Spine
Volume17
Issue number1 Suppl
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Riluzole
Clinical Trials, Phase I
Spinal Cord Injuries
Clinical Trials
Tissue Preservation
Therapeutics
Sodium Channels
Amyotrophic Lateral Sclerosis
Neuroprotective Agents
Pharmaceutical Preparations
Pharmacokinetics
Safety
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fehlings, M. G., Wilson, J. R., Frankowski, R. F., Toups, E. G., Aarabi, B., Harrop, J. S., ... Grossman, R. G. (2012). Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. Journal of neurosurgery. Spine, 17(1 Suppl), 151-156.

Riluzole for the treatment of acute traumatic spinal cord injury : rationale for and design of the NACTN Phase I clinical trial. / Fehlings, Michael G.; Wilson, Jefferson R.; Frankowski, Ralph F.; Toups, Elizabeth G.; Aarabi, Bizhan; Harrop, James S.; Shaffrey, Christopher I.; Harkema, Susan J.; Guest, James D; Tator, Charles H.; Burau, Keith D.; Johnson, Michele W.; Grossman, Robert G.

In: Journal of neurosurgery. Spine, Vol. 17, No. 1 Suppl, 01.09.2012, p. 151-156.

Research output: Contribution to journalArticle

Fehlings, MG, Wilson, JR, Frankowski, RF, Toups, EG, Aarabi, B, Harrop, JS, Shaffrey, CI, Harkema, SJ, Guest, JD, Tator, CH, Burau, KD, Johnson, MW & Grossman, RG 2012, 'Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.', Journal of neurosurgery. Spine, vol. 17, no. 1 Suppl, pp. 151-156.
Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. Journal of neurosurgery. Spine. 2012 Sep 1;17(1 Suppl):151-156.
Fehlings, Michael G. ; Wilson, Jefferson R. ; Frankowski, Ralph F. ; Toups, Elizabeth G. ; Aarabi, Bizhan ; Harrop, James S. ; Shaffrey, Christopher I. ; Harkema, Susan J. ; Guest, James D ; Tator, Charles H. ; Burau, Keith D. ; Johnson, Michele W. ; Grossman, Robert G. / Riluzole for the treatment of acute traumatic spinal cord injury : rationale for and design of the NACTN Phase I clinical trial. In: Journal of neurosurgery. Spine. 2012 ; Vol. 17, No. 1 Suppl. pp. 151-156.
@article{24203e2f695e4523a0090abed7cf2616,
title = "Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.",
abstract = "In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of glutamatergic toxicity, is currently an approved drug that attenuates the extent of neuronal degeneration in patients with amyotrophic lateral sclerosis. Moreover, several preclinical SCI studies have associated riluzole administration with improved functional outcomes and increased neural tissue preservation. Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. The current review summarizes the existing preclinical and clinical literature on riluzole, provides a detailed description of the Phase I trial, and suggests potential opportunities for future investigation. Clinical trial registration no.: NCT00876889.",
author = "Fehlings, {Michael G.} and Wilson, {Jefferson R.} and Frankowski, {Ralph F.} and Toups, {Elizabeth G.} and Bizhan Aarabi and Harrop, {James S.} and Shaffrey, {Christopher I.} and Harkema, {Susan J.} and Guest, {James D} and Tator, {Charles H.} and Burau, {Keith D.} and Johnson, {Michele W.} and Grossman, {Robert G.}",
year = "2012",
month = "9",
day = "1",
language = "English",
volume = "17",
pages = "151--156",
journal = "Journal of Neurosurgery: Spine",
issn = "1547-5654",
publisher = "American Association of Neurological Surgeons",
number = "1 Suppl",

}

TY - JOUR

T1 - Riluzole for the treatment of acute traumatic spinal cord injury

T2 - rationale for and design of the NACTN Phase I clinical trial.

AU - Fehlings, Michael G.

AU - Wilson, Jefferson R.

AU - Frankowski, Ralph F.

AU - Toups, Elizabeth G.

AU - Aarabi, Bizhan

AU - Harrop, James S.

AU - Shaffrey, Christopher I.

AU - Harkema, Susan J.

AU - Guest, James D

AU - Tator, Charles H.

AU - Burau, Keith D.

AU - Johnson, Michele W.

AU - Grossman, Robert G.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of glutamatergic toxicity, is currently an approved drug that attenuates the extent of neuronal degeneration in patients with amyotrophic lateral sclerosis. Moreover, several preclinical SCI studies have associated riluzole administration with improved functional outcomes and increased neural tissue preservation. Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. The current review summarizes the existing preclinical and clinical literature on riluzole, provides a detailed description of the Phase I trial, and suggests potential opportunities for future investigation. Clinical trial registration no.: NCT00876889.

AB - In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of glutamatergic toxicity, is currently an approved drug that attenuates the extent of neuronal degeneration in patients with amyotrophic lateral sclerosis. Moreover, several preclinical SCI studies have associated riluzole administration with improved functional outcomes and increased neural tissue preservation. Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. The current review summarizes the existing preclinical and clinical literature on riluzole, provides a detailed description of the Phase I trial, and suggests potential opportunities for future investigation. Clinical trial registration no.: NCT00876889.

UR - http://www.scopus.com/inward/record.url?scp=84872202507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872202507&partnerID=8YFLogxK

M3 - Article

C2 - 22985381

AN - SCOPUS:84872202507

VL - 17

SP - 151

EP - 156

JO - Journal of Neurosurgery: Spine

JF - Journal of Neurosurgery: Spine

SN - 1547-5654

IS - 1 Suppl

ER -